Target General Infomation
Target ID
T18226
Target Name
HUMAN clathrin-mediated endocytosis (RME)
Target Status
Target in Phase 3 Trial
[1]
Disease [+] 3 Target-related Diseases +
1 COVID-19 [ICD-11: 1D6Y]
2 Middle East Respiratory Syndrome [ICD-11: 1D64]
3 Severe acute respiratory syndrome [ICD-11: 1D65]
Drugs and Modes of Action
Drugs in Phase 3 Trial [+] 1 Drugs in Phase 3 Trial +
1 Chlorpromazine Drug Info Phase 3 Trial COVID-19 [2]
Investigative agents [+] 4 Investigative agents +
1 Triflupromazine Drug Info Investigative MERS [3]
2 Thiethylperazine Drug Info Investigative MERS [3]
3 Fluphenazine Drug Info Investigative MERS [4]
4 Promethazine Drug Info Investigative MERS [3]
Mode of Action [+] 1 Modes of Action +
Inhibitor [+] 5 Inhibitor drugs +
1 Chlorpromazine Drug Info [1], [5]
2 Fluphenazine Drug Info [3], [4]
3 Promethazine Drug Info [6]
4 Thiethylperazine Drug Info [3]
5 Triflupromazine Drug Info [3]
References
1 Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19. Int J Biol Sci. 2020 Mar 15;16(10):1724-1731.
2 ClinicalTrials.gov (NCT04366739) Repurposing of Chlorpromazine in Covid-19 Treatment. U.S. National Institutes of Health.
3 Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93.
4 Testing of Middle East respiratory syndrome coronavirus replication inhibitors for the ability to block viral entry. Antimicrob Agents Chemother. 2015 Jan;59(1):742-4.
5 Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
6 Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.